Łotwa - łotewski - Zāļu valsts aģentūra

zentiva, k.s., czech republic - ezetimibum, atorvastatinum - tablete - 10 mg/80 mg

Łotwa - łotewski - Zāļu valsts aģentūra

sandoz d.d., slovenia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/20 mg

Łotwa - łotewski - Zāļu valsts aģentūra

sandoz d.d., slovenia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/40 mg

Łotwa - łotewski - Zāļu valsts aģentūra

olainfarm, as, latvia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/10 mg

Łotwa - łotewski - Zāļu valsts aģentūra

olainfarm, as, latvia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/20 mg

Łotwa - łotewski - Zāļu valsts aģentūra

olainfarm, as, latvia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/40 mg

Łotwa - łotewski - Zāļu valsts aģentūra

olainfarm, as, latvia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/80 mg

Unia Europejska - łotewski - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - colesevelam (as hydrochloride) - hiperholesterolēmija - lipīdu modificējoši aģenti - cholestagel kopīgi pārvalda ar 3-hydroxy-3-methyl-glutaryl-coenzyme-a (hmg-coa)-reduktāzes inhibitors (statīnu) ir norādīts kā palīglīdzekļa terapijas diētu sniegt piedevu zemākā-density-lipoproteīna-holesterīns (ldl c) līmeņa samazināšanos pieaugušiem pacientiem ar primāro hypercholesterolaemia, kas netiek pienācīgi kontrolēts ar statīnu vienatnē. cholestagel kā monotherapy ir norādīts kā adjunctive terapiju, lai diēta, lai samazināt paaugstināts kopējā holesterīna un zbl-c pieaugušo pacientiem ar primāro hypercholesterolaemia, kuriem statin tiek uzskatīta par nepiemērotu, vai nav labi panesams. cholestagel var izmantot arī kopā ar ezetimibe, ar vai bez statin, pieaugušiem pacientiem ar primāro hypercholesterolaemia, tostarp pacientiem ar ģimenes hypercholesterolaemia (skatīt 5. iedaļu.

Unia Europejska - łotewski - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics sistēmiskai lietošanai - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 un 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 un 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 un 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 un 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 un 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 un 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 un 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazīvās aspergillosis pacientiem ar slimību, kas ir ugunsizturīgi, lai amfotericīna b vai itraconazole, vai pacientiem, kuri nepanes no šīm zālēm;- fusariosis pacientiem ar slimību, kas ir ugunsizturīgi, lai amfotericīna b, vai pacientiem, kuri nepanes no amfotericīna b;- chromoblastomycosis un mycetoma pacientiem ar slimību, kas ir ugunsizturīgi, lai itraconazole, vai pacientiem, kuri nepanes no itraconazole;- coccidioidomycosis pacientiem ar slimību, kas ir ugunsizturīgi, lai amfotericīna b, itraconazole vai fluconazole, vai pacientiem, kuri nepanes no šīm zālēm;- orofaringālas kandidoze: kā pirmās līnijas terapija pacientiem, kuriem ir smagas slimības vai pat cilvēkiem ar traucētu imūnsistēmu, kuriem atbildes uz aktuāliem terapija ir sagaidāms, ka būs slikti. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Łotwa - łotewski - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - amlodipinum, atorvastatinum - apvalkotās tabletes - 10 mg/10 mg